Trials / Conditions / Relapsed/Refractory

Relapsed/Refractory

7 registered clinical trials studyying Relapsed/Refractory — 4 currently recruiting.

Status	Trial	Sponsor	Phase
Not Yet Recruiting	A Phase 1 Study Of FLAG Chemotherapy In Combination With Lisaftoclax And Pelcitoclax In Patients With Relapsed NCT07428486	M.D. Anderson Cancer Center	Phase 1
Recruiting	Chimeric Antigen Receptor Modified T Cells Targeting BCMA for the Treatment of Relapsed/Refractory Multiple My NCT06581640	The First Affiliated Hospital of Xiamen University	Phase 2
Recruiting	A Study to Evaluate CG-105-12 in Patients With Relapsed/Refractory Multiple Myeloma NCT06999031	The First Affiliated Hospital of Nanchang University	EARLY_Phase 1
Recruiting	Phase Ib/II Study Assessing the Clinical Activity and Safety of Brexucabtagene Autoleucel as a Consolidation i NCT06287229	M.D. Anderson Cancer Center	Phase 1 / Phase 2
Completed	Pilot Prospective Study for PET-CT Imaging in Participants With Relapsed/Refractory Acute Leukemias NCT05969002	National Cancer Institute (NCI)	—
Completed	A Study to Investigate the Safety, Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of TAK-079 Adm NCT03439280	Millennium Pharmaceuticals, Inc.	Phase 1 / Phase 2
Terminated	Testing JNJ-42756493 In Combination With Dexamethasone in Multiple Myeloma That Came Back After a Period of Im NCT02952573	University Health Network, Toronto	Phase 2